Palavras-chave
Como Citar
Resumo
Liver cirrhosis caused by hepatitis C is a serious condition that often leads to the need for liver transplantation for patients in advanced stages of the disease. This procedure has been a crucial measure to improve survival and quality of life for these patients. However, its effectiveness and impact are the subject of critical analysis due to the associated challenges, such as the scarcity of donor organs, the risks of postoperative complications and the possibility of recurrence of hepatitis C virus infection in the new liver. Understanding the advantages and challenges of liver transplantation in hepatitis C liver cirrhosis is essential to optimize patient outcomes and quality of life. Objective: To critically analyze the advantages, challenges and impact on the quality of life of patients undergoing liver transplantation due to liver cirrhosis caused by hepatitis C. Methodology: A systematic literature review was carried out following the PRISMA guidelines. The PubMed, Scielo and Web of Science databases were searched for articles published in the last 10 years. The descriptors used were "liver transplant", "liver cirrhosis", "hepatitis C", "advantages", "challenges" and "quality of life". The inclusion criteria were original studies that addressed the topic in humans, written in English, Portuguese or Spanish. Exclusion criteria were animal studies, literature reviews and studies focusing on liver conditions other than hepatitis C. Results: The results highlighted the effectiveness of liver transplantation in improving the survival and quality of life of patients with liver cirrhosis due to hepatitis C. However, challenges persist, including the limited availability of donor organs and the risk of relapse of hepatitis C virus infection. Strategies to mitigate these challenges have been discussed, such as the use of next-generation antiviral therapies. Conclusion: Liver transplantation is a vital intervention for patients with liver cirrhosis caused by hepatitis C, providing significant benefits in terms of survival and quality of life. However, the associated challenges need to be addressed to further improve outcomes and ensure the long-term success of this procedure.
Referências
Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: from discovery to cure. Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):533-550. doi: 10.1038/s41575-022-00608-8.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:. EASL recommendations on treatment of hepatitis C: Final update of the series☆. J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018.
Burra P, De Martin E, Zanetto A, Senzolo M, Russo FP, Zanus G, Fagiuoli S. Hepatitis C virus and liver transplantation: where do we stand? Transpl Int. 2016 Feb;29(2):135-52. doi: 10.1111/tri.12642. AND
Filipec Kanizaj T, Kunac N. Hepatitis C: New challenges in liver transplantation. World J Gastroenterol. 2015 May 21;21(19):5768-77. doi: 10.3748/wjg.v21.i19.5768.
Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges. United European Gastroenterol J. 2019 Jun;7(5):642-650. doi: 10.1177/2050640619840149.
Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, Pasulo L. Management of hepatitis C infection before and after liver transplantation. World J Gastroenterol. 2015 Apr 21;21(15):4447-56. doi: 10.3748/wjg.v21.i15.4447.
Dhanasekaran R, Firpi RJ. Challenges of recurrent hepatitis C in the liver transplant patient. World J Gastroenterol. 2014 Apr 7;20(13):3391-400. doi: 10.3748/wjg.v20.i13.3391.
Li J, Wu V, Pan CQ. Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review. Hepatol Int. 2022 Oct;16(5):1020-1031. doi: 10.1007/s12072-022-10380-1.
Khan R, Singal AK, Anand BS. Outcomes after liver transplantation for combined alcohol and hepatitis C virus infection. World J Gastroenterol. 2014 Sep 14;20(34):11935-8. doi: 10.3748/wjg.v20.i34.11935. P
McCarty TR, Lim JK. Developing therapies to treat hepatitis C infection in post-liver transplant recipients. Expert Opin Pharmacother. 2017 Feb;18(2):165-174. doi: 10.1080/14656566.2016.1276564.
Conde I, Vinaixa C, Berenguer M. Hepatitis C-related cirrhosis. Current status. Med Clin (Barc). 2017 Jan 20;148(2):78-85. English, Spanish. doi: 10.1016/j.medcli.2016.09.019.
Conde I, Vinaixa C, Berenguer M. Hepatitis C-related cirrhosis. Current status. Med Clin (Barc). 2017 Jan 20;148(2):78-85. English, Spanish. doi: 10.1016/j.medcli.2016.09.019.
Aguilera V, Di Maira T, Conde I, Fornés-Ferrer V, Vinaixa C, Pallarés C, Carvalho-Gomes A, Cubells A, García M, Rubín Á, Benlloch S, Gonzalez-Dieguez L, Molina JM, Puchades L, López -Labrador FX, Prieto M, Berenguer M. Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk - an observational, retrospective study. Transpl Int. 2018 Jun;31(6):649-657. doi: 10.1111/tri.13145.
Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015 May;12(5):284-92. doi: 10.1038/nrgastro.2015.53.
Coilly A, Roche B, Duclos-Vallée JC, Samuel D. News and challenges in the treatment of hepatitis C in liver transplantation. Liver Int 2016 Jan;36 Suppl 1:34-42. doi: 10.1111/liv.13017.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Felipe Leão Martins Amaral, Larissa Carla Leão Cruvinel Delfino, Júlia Cristina de Sousa Ramos, Lethícia Costa Pardinho, Maria Eduarda dos Santos Cardoso, Aline Moreira Moraes, Eduardo Henrique Mendes Rezende, Luiz Augusto Germano Borges, Murilo Dell Eugenio Costa Filho, Daniel Oliveira Silva